All In Biotech

Drug Trial Radar · NCT03308968

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 838 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

838

Actual

Start

Oct 13, 2017

Primary completion

Oct 2, 2018

Study completion May 29, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in participants with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments. Approximately equal numbers of participants from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of 3 treatments for the subgroup - 2 active treatments and 1 placebo treatment- consisting of monthly injections for 3 months (up to Week 12). Then all participants continue into an open-label extension of 3 months (up to Week 24) during which everyone is administered sc injections of fremanezumab.

Conditions

  • Migraine Prophylaxis

Interventions

  • FremanezumabDrug

    Fremanezumab will be administered per dose and schedule specified in the arm.

  • PlaceboDrug

    Placebo matching to fremanezumab will be administered per schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of FremanezumabTime frame: Baseline (Day -28 to Day -1), up to Week 12

Locations

113 sites in 14 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 14742

    Huntsville, Alabama

  • Teva Investigational Site 14729

    Long Beach, California

  • Teva Investigational Site 14739

    San Diego, California

  • Teva Investigational Site 14843

    Santa Monica, California

  • Teva Investigational Site 14749

    Colorado Springs, Colorado

  • Teva Investigational Site 14758

    Maitland, Florida

  • Teva Investigational Site 14738

    Orlando, Florida

  • Teva Investigational Site 14760

    Decatur, Georgia

  • Teva Investigational Site 14737

    Meridian, Idaho

  • Teva Investigational Site 14730

    Chicago, Illinois

  • Teva Investigational Site 14740

    Evanston, Illinois

  • Teva Investigational Site 14735

    Louisville, Kentucky

  • Teva Investigational Site 14747

    Pikesville, Maryland

  • Teva Investigational Site 14750

    Fall River, Massachusetts

  • Teva Investigational Site 14734

    Watertown, Massachusetts

  • Teva Investigational Site 14731

    Ann Arbor, Michigan

  • Teva Investigational Site 14748

    Plymouth, Minnesota

  • Teva Investigational Site 14746

    Omaha, Nebraska

  • Teva Investigational Site 14754

    Berlin, New Jersey

  • Teva Investigational Site 14752

    Albuquerque, New Mexico

  • Teva Investigational Site 14753

    Amherst, New York

  • Teva Investigational Site 14736

    Greensboro, North Carolina

  • Teva Investigational Site 14741

    Greensboro, North Carolina

  • Teva Investigational Site 14732

    Raleigh, North Carolina

  • Teva Investigational Site 14761

    Lincoln, Rhode Island

  • Teva Investigational Site 14756

    Warwick, Rhode Island

  • Teva Investigational Site 14745

    Memphis, Tennessee

  • Teva Investigational Site 14743

    Nashville, Tennessee

  • Teva Investigational Site 14733

    Austin, Texas

  • Teva Investigational Site 14751

    West Jordan, Utah

  • Teva Investigational Site 37092

    Bruges, Belgium

  • Teva Investigational Site 37089

    Brussels, Belgium

  • Teva Investigational Site 37091

    Hasselt, Belgium

  • Teva Investigational Site 37090

    Liège, Belgium

  • Teva Investigational Site 54162

    Brno, Czechia

  • Teva Investigational Site 54159

    Ostrava, Czechia

  • Teva Investigational Site 54165

    Ostrava-Moravska, Czechia

  • Teva Investigational Site 54158

    Pardubice, Czechia

  • Teva Investigational Site 54163

    Prague, Czechia

  • Teva Investigational Site 54161

    Prague, Czechia

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.